Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean People
Active, not recruiting
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT06587464
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul,, Korea, Republic of
A Study of Freeze-dried Human Protein C Concentrate (TAK-662) in Participants with Congenital Protein C Deficiency
Recruiting
- Conditions
- Protein C Deficiency
- Interventions
- Drug: Freeze-dried Human Protein C Concentrate
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 7
- Registration Number
- NCT06590974
- Locations
- 🇯🇵
Takeda selected site, Tokyo, Japan
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Phase 4
Not yet recruiting
- Conditions
- Ulcerative ColitisCrohn's Disease
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 400
- Registration Number
- NCT06581328
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Phase 3
Not yet recruiting
- Conditions
- Dengue Fever
- Interventions
- Biological: TDVOther: Placebo
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 800
- Registration Number
- NCT06579755
A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 250
- Registration Number
- NCT06577363
- Locations
- 🇯🇵
Takeda selected site, Tokyo, Japan
A Study of Cytomegalovirus (CMV) Infection After Kidney Transplant in Adults in the United Kingdom
Recruiting
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 672
- Registration Number
- NCT06568055
- Locations
- 🇬🇧
RaDaR (part of the UK Kidney Association), Bristol, Southwestern England, United Kingdom
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Not yet recruiting
- Conditions
- Primary Immunodeficiency Diseases (PID)
- Interventions
- Drug: Immune Globulin Subcutaneous (Human), 20% Solution
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 100
- Registration Number
- NCT06565078
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 78
- Registration Number
- NCT06562543
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 168
- Registration Number
- NCT06555432
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 9
- Registration Number
- NCT06550882
© Copyright 2025. All Rights Reserved by MedPath